Table 5 |
||||||||
|
Blood lipid data of men (A) and women (B) before and following three weeks of supplementation with Ambrotose AO® at a dosage of 4 capsules per day and placebo (cross-over design with a three week washout between conditions). |
||||||||
|
A |
||||||||
|
|
||||||||
|
Variable |
Trained Men Ambrotose AO® Pre |
Trained Men Ambrotose AO® Post |
Trained Men Placebo Pre |
Trained Men Placebo Post |
Untrained Men Ambrotose AO® Pre |
Untrained Men Ambrotose AO® Post |
Untrained Men Placebo Pre |
Untrained Men Placebo Post |
|
|
||||||||
|
Cholesterol (mg·dL-1)† |
155.7 ± 9.7 |
149.0 ± 5.4 |
160.7 ± 12.1 |
159.9 ± 9.6 |
173.0 ± 13.6 |
169.8 ± 16.4 |
171.2 ± 13.6 |
173.6 ± 16.1 |
|
Triglycerides (mg·dL-1)* |
82.3 ± 11.6 |
93.6 ± 16.4 |
98.7 ± 17.7 |
95.3 ± 14.5 |
103.6 ± 31.6 |
80.2 ± 16.8 |
69.2 ± 10.6 |
94.0 ± 32.3 |
|
HDL-C (mg·dL-1)* |
44.7 ± 2.9 |
45.1 ± 3.5 |
45.2 ± 3.0 |
47.0 ± 3.6 |
51.2 ± 6.1 |
53.0 ± 3.8 |
51.8 ± 4.0 |
46.2 ± 5.7 |
|
VLDL-C (mg·dL-1)* |
16.6 ± 2.3 |
18.6 ± 3.2 |
19.7 ± 3.5 |
19.1 ± 2.8 |
20.8 ± 6.4 |
16.0 ± 3.4 |
14.0 ± 2.0 |
18.8 ± 6.5 |
|
LDL-C (mg·dL-1)†* |
94.4 ± 8.5 |
85.3 ± 3.9 |
95.6 ± 9.8 |
93.7 ± 8.0 |
101.0 ± 13.2 |
100.8 ± 15.4 |
105.4 ± 13.7 |
108.6 ± 16.2 |
|
LDL/HDL* |
2.2 ± 0.3 |
2.0 ± 0.2 |
2.2 ± 0.3 |
2.1 ± 0.3 |
2.2 ± 0.6 |
2.0 ± 0.4 |
2.1 ± 0.5 |
2.7 ± 0.7 |
|
|
||||||||
|
B |
||||||||
|
|
||||||||
|
Variable |
Trained Women Ambrotose AO® Pre |
Trained Women Ambrotose AO® Post |
Trained Women Placebo Pre |
Trained Women Placebo Post |
Untrained Women Ambrotose AO® Pre |
Untrained Women Ambrotose AO® Post |
Untrained Women Placebo Pre |
Untrained Women Placebo Post |
|
Cholesterol (mg·dL-1)† |
153.0 ± 5.8 |
146.7 ± 12.6 |
160.0 ± 14.2 |
154.7 ± 11.4 |
169.7 ± 9.4 |
167.7 ± 10.1 |
174.0 ± 6.4 |
175.3 ± 7.3 |
|
Triglycerides (mg·dL-1)* |
56.0 ± 6.9 |
52.1 ± 6.1 |
69.1 ± 11.2 |
66.3 ± 10.5 |
66.0 ± 8.6 |
70.3 ± 20.6 |
63.0 ± 11.4 |
71.5 ± 20.8 |
|
HDL-C (mg·dL-1)* |
65.1 ± 4.3 |
63.1 ± 6.7 |
65.1 ± 7.6 |
61.7 ± 6.7 |
60.9 ± 3.5 |
62.8 ± 5.6 |
64.3 ± 6.1 |
69.2 ± 6.3 |
|
VLDL-C (mg·dL-1)* |
11.3 ± 1.4 |
10.4 ± 1.2 |
14.0 ± 2.3 |
13.3 ± 2.2 |
13.1 ± 1.8 |
14.0 ± 4.1 |
12.8 ± 2.3 |
14.2 ± 4.1 |
|
LDL-C (mg·dL-1)†* |
76.6 ± 5.5 |
73.1 ± 6.1 |
80.9 ± 6.9 |
79.7 ± 6.4 |
95.7 ± 9.0 |
90.8 ± 9.3 |
96.8 ± 7.9 |
92.0 ± 8.7 |
|
LDL/HDL* |
1.2 ± 0.1 |
1.2 ± 0.1 |
1.3 ± 0.1 |
1.3 ± 0.1 |
1.6 ± 0.1 |
1.5 ± 0.2 |
1.6 ± 0.2 |
1.4 ± 0.2 |
|
|
||||||||
|
Values are mean ± SEM. † Training status effect: Cholesterol (p = 0.009); LDL-C (p = 0.009) * Sex effect: Triglycerides (p = 0.0005); HDL-C (p < 0.0001); VLDL-C (p = 0.0006); LDL-C (p = 0.002); LDL/HDL (p < 0.001) No other statistically significant differences were noted (p > 0.05). |
||||||||
|
Bloomer et al. Nutrition Journal 2010 9:49 doi:10.1186/1475-2891-9-49 |
||||||||
